5-Amino-1MQ 50mg

5-Amino-1MQ 50 mg is a high-purity synthetic small-molecule research compound supplied by Grail Formula for scientific investigation and controlled laboratory experimentation involving nicotinamide N-methyltransferase (NNMT), cellular metabolism and methylation-associated biochemical pathways.

For research use only — not for human or veterinary use.

 

Product Overview

5-Amino-1MQ, also known as 5-amino-1-methylquinolinium, is a synthetic quinolinium-based compound investigated in experimental research involving nicotinamide N-methyltransferase inhibition, metabolic regulation and intracellular methylation processes.

Unlike peptide-based research compounds, 5-Amino-1MQ is a small organic molecule. Its scientific relevance arises primarily from investigations into NNMT, an enzyme associated with nicotinamide metabolism and the transfer of methyl groups from S-adenosyl-L-methionine (SAM) to suitable molecular substrates.

Grail Formula supplies 5-Amino-1MQ 50 mg as a nominal 50 mg research preparation intended for controlled laboratory experimentation and biochemical investigations.

Independent third-party analytical testing was conducted by Liquilabs s.r.o., Czechia. The Certificate of Analysis, published on 11 October 2026, identifies production batch GF-5AM50-B243 and reports a measured assay content of 51.2 mg with chromatographic purity of greater than 99.8 %.

The measured assay content exceeds the nominal 50 mg designation by 1.2 mg, corresponding to a 2.4 % positive difference. This result is disclosed separately from the chromatographic purity measurement.

The Certificate of Analysis also reports a bacterial endotoxin level of 0.350 EU/mg, with a stated uncertainty of ± 0.007 EU/mg. This measurable result falls within the laboratory’s reported acceptable range of 0–0.5 EU/mg but must not be interpreted as evidence of sterility or suitability for administration.

 

Compound Overview

5-Amino-1MQ belongs to the family of substituted quinolinium compounds and is investigated as a small-molecule inhibitor of nicotinamide N-methyltransferase.

NNMT is a cytosolic enzyme that catalyses the transfer of a methyl group from S-adenosyl-L-methionine to nicotinamide, producing 1-methylnicotinamide and S-adenosyl-L-homocysteine.

This enzymatic reaction connects nicotinamide metabolism with cellular methyl-donor utilisation, making NNMT relevant to experimental studies involving metabolic pathways and methylation-associated biochemical regulation.

5-Amino-1MQ has attracted scientific attention because its molecular structure has been investigated in relation to NNMT inhibition and changes in enzyme-associated metabolic processes.

As a synthetic small molecule, its chemical characteristics differ from those of peptide hormones, regulatory peptides and protein-derived research compounds.

Its relatively low molecular mass and defined quinolinium structure make it suitable for analytical investigations involving chromatographic separation, molecular identity assessment and quantitative chemical analysis.

Scientific studies involving 5-Amino-1MQ have examined NNMT-associated pathways in biochemical systems, cultured cells and preclinical experimental models.

These findings are dependent on experimental conditions and do not establish therapeutic efficacy, clinical safety or suitability for human or veterinary use.

 

Historical Background and Scientific Context

Research into nicotinamide metabolism has developed through investigations of vitamin B3-associated biochemical pathways, cellular energy regulation and the metabolism of nicotinamide-containing compounds.

NNMT became an important subject of scientific interest because of its role in the methylation of nicotinamide and its connection to the cellular availability and utilisation of methyl donors.

Advances in enzymology and molecular biology enabled researchers to characterise NNMT activity, investigate its tissue distribution and examine its relationship with broader metabolic regulatory systems.

Subsequent research explored associations between NNMT expression, cellular metabolism and experimental models involving adipose tissue, metabolic adaptation and altered biochemical conditions.

The development of selective small-molecule NNMT inhibitors provided researchers with additional tools for investigating the contribution of this enzyme to intracellular metabolic pathways.

5-Amino-1MQ emerged within this field of experimental inhibitor research as a compound investigated for its ability to interfere with NNMT-associated enzymatic activity.

Preclinical studies have examined the relationship between NNMT inhibition and metabolic changes in experimental systems. These investigations have contributed to scientific interest in the enzyme’s role in cellular methylation and metabolic regulation.

Research has also examined NNMT in connection with the relationship between nicotinamide metabolism, S-adenosyl-L-methionine utilisation and the production of methylated metabolites.

These biochemical connections have encouraged further investigation into how enzyme activity may influence metabolic networks under different experimental conditions.

Despite the expanding research literature, findings involving NNMT inhibitors remain dependent on the particular compound, biological model, experimental design and measured endpoints.

Results from preclinical studies should not be interpreted as establishing equivalent effects in humans or as demonstrating clinical benefits for a research-grade compound.

 

Mechanistic Focus in Research

The principal mechanistic focus of 5-Amino-1MQ research concerns its interaction with nicotinamide N-methyltransferase and the biochemical pathways associated with NNMT-mediated methylation.

NNMT enzyme inhibition

NNMT catalyses the transfer of a methyl group from S-adenosyl-L-methionine to nicotinamide, generating 1-methylnicotinamide and S-adenosyl-L-homocysteine.

Experimental inhibition of this enzyme provides a method for investigating the contribution of NNMT activity to nicotinamide metabolism and cellular methylation-associated processes.

Researchers may examine changes in substrate availability, product formation and enzyme-associated biochemical activity under controlled experimental conditions.

Methyl-donor metabolism

Because NNMT uses S-adenosyl-L-methionine as a methyl donor, its activity is relevant to investigations involving cellular methyl-group utilisation.

Laboratory research may explore relationships between NNMT-associated reactions, methyl-donor availability and broader metabolic regulatory networks.

These investigations contribute to understanding how individual enzymatic pathways interact with cellular biochemical systems.

Nicotinamide-associated metabolic pathways

Nicotinamide is connected to the broader metabolic network involving nicotinamide adenine dinucleotide (NAD+), an essential cofactor in numerous cellular biochemical reactions.

NNMT-mediated nicotinamide methylation is one component of this metabolic network, making NNMT inhibition relevant to experimental investigations of nicotinamide utilisation and related metabolite profiles.

However, changes in NNMT activity do not automatically establish a predictable increase in cellular NAD+ concentrations or a particular biological outcome.

Cellular metabolic regulation

Preclinical research has investigated NNMT-associated pathways in experimental models involving metabolic regulation, adipose tissue biology and intracellular biochemical adaptation.

Researchers examine these models to distinguish enzyme-specific effects from broader changes in cellular metabolism.

The observed responses depend on the experimental model, inhibitor concentration, biological environment and analytical methods employed.

The supplied Certificate of Analysis documents the chemical identity, measured quantity, chromatographic purity and selected microbiological and elemental impurity characteristics of the tested sample. It does not contain an NNMT enzyme inhibition assay, an IC50 measurement or biological activity data demonstrating a particular mechanistic effect for this batch.

 

Analytical Verification (COA)

Grail Formula supports batch-specific analytical transparency through independent third-party laboratory testing. The 5-Amino-1MQ 50 mg Certificate of Analysis was issued by Liquilabs s.r.o., Czechia, with a publication date of 11 October 2026.

The report identifies sample LYO-1011, batch GF-5AM50-B243, and documents compound assay content, chromatographic purity, FTIR identification, retention time assessment, molecular ion mass identification, microbiological counts, bacterial endotoxins and elemental impurities.

Compound assay and chromatographic purity

• Nominal product quantity: 50 mg
• Measured 5-amino-1-methylquinolinium assay content: 51.2 mg ± 0.3 mg
• Reported compound purity: greater than 99.8 %
• Measured assay difference from nominal quantity: 1.2 mg above the labelled 50 mg
• Measured assay as a proportion of nominal quantity: 102.4 %
• Analytical screening designation: Peptide Screening 0.1% TFA, as stated in the report

The measured assay content represents a 2.4 % positive difference relative to the nominal 50 mg quantity. This finding is reported independently of the chromatographic purity result.

The reported purity of greater than 99.8 % describes the chromatographic composition under the applied analytical conditions. It does not represent the percentage of the nominal quantity recovered during assay testing.

Although the laboratory’s results table uses a peptide-screening designation, 5-Amino-1MQ is chemically a small-molecule compound rather than a peptide.

Compound identity assessment

• FTIR spectrum identification result: 991 ± 5, as reported
• Retention time identification result: 0.992 ± 0.005, as reported
• Molecular ion mass identification: 159 Da ± 1 Da
• Mass spectrometry identity assessment: MS deconvolution

The Certificate of Analysis includes chromatographic and mass spectrometric documentation supporting the analytical characterisation of the tested compound.

The FTIR and retention time identification values are reproduced as reported. The summary does not provide separate explicit pass/fail interpretations for these measurements.

The molecular ion mass identification result of 159 Da is reported as an analytical identity measurement and should not be confused with the measured compound quantity of 51.2 mg.

Bacterial endotoxin and microbiological assessment

• Bacterial endotoxin: 0.350 EU/mg ± 0.007 EU/mg
• Reported endotoxin acceptable range: 0–0.5 EU/mg
• Total aerobic microbial count: 0 CFU/g
• Total yeast and mould count: 0 CFU/g
• Reported aerobic microbial count range: 0–1000 CFU/g
• Reported yeast and mould count range: 0–100 CFU/g

Microbiological testing references USP <61> / European Pharmacopoeia 2.6.12 plate-count methodology. Bacterial endotoxin determination references USP <85> / European Pharmacopoeia 2.6.14 chromogenic testing.

Both microbiological counts were reported as zero under the applied testing conditions. Bacterial endotoxin was measurable at 0.350 EU/mg, representing 70 % of the laboratory’s stated upper acceptable limit of 0.5 EU/mg.

Although the endotoxin result falls within the stated laboratory range, its measurable concentration should be reported transparently. The findings do not establish sterility, biological safety or suitability for administration.

Elemental impurity screening

Seven elemental impurities were evaluated using screening procedures referenced to USP <232> and European Pharmacopoeia 5.20 / 2.4.20.

• Arsenic: below 0.001 ppm
• Cadmium: below 0.001 ppm
• Mercury (listed as quicksilver): below 0.001 ppm
• Lead: below 0.001 ppm
• Nickel: below 0.001 ppm
• Vanadium: below 0.001 ppm
• Cobalt: below 0.001 ppm

All seven reported elemental impurity results were below 0.001 ppm and within their respective stated acceptable ranges.

Results below the analytical reporting threshold indicate concentrations below the specified level rather than confirmation of absolute absence.

The complete 13-page Certificate of Analysis contains analytical method specifications, chromatographic documentation, mass spectrometric records, endotoxin determination information and microbiological methodology descriptions.

 

Research Applications

5-Amino-1MQ is investigated in experimental biochemistry, enzyme inhibition research and cellular metabolic studies. Its scientific relevance arises from its association with NNMT inhibition and the biochemical pathways involving nicotinamide methylation.

Potential areas of laboratory investigation include:

• Nicotinamide N-methyltransferase enzyme inhibition research
• Nicotinamide-associated metabolic pathway investigations
• Cellular methyl-donor utilisation and SAM-associated metabolism
• Experimental NNMT substrate and product analysis
• Small-molecule enzyme inhibitor characterisation
• Preclinical cellular metabolic regulation studies
• Structure-activity relationships of quinolinium compounds
• Analytical identity, purity and quantitative compound assessment

These applications represent scientific research directions rather than demonstrated therapeutic benefits. Individual experiments require suitable controls, validated measurement endpoints and careful interpretation of results.

Batch-specific analytical documentation can support laboratory recordkeeping and assist researchers in evaluating the reported characteristics of the tested preparation.

 

Grail Formula Quality

Grail Formula focuses on supplying laboratory research compounds supported by transparent product information and independently documented analytical findings.

For 5-Amino-1MQ 50 mg, independent Liquilabs testing provides measured information concerning compound assay content, chromatographic purity, analytical identity, bacterial endotoxin levels, microbiological counts and selected elemental impurities.

The report documents a measured assay content of 51.2 mg against the nominal 50 mg quantity and a bacterial endotoxin result of 0.350 EU/mg. Both results are disclosed as part of the batch-specific analytical profile.

Each finding should be interpreted within the scope of the tested sample, the applied analytical methodology and the reported measurement uncertainty.

Transparent reporting of analytical findings supports informed laboratory assessment and appropriate research documentation.

 

When You Choose Grail Formula

Choosing Grail Formula means selecting a research compound accompanied by independently documented, batch-specific analytical information rather than relying solely on general product specifications.

For this 5-Amino-1MQ preparation, researchers can review the Liquilabs Certificate of Analysis to examine the reported purity, measured compound content, identity assessment, microbiological findings and elemental impurity screening.

The report provides a defined batch reference and publication date, allowing the analytical findings to be associated with the identified production batch.

Grail Formula emphasises factual product presentation, research-oriented documentation and transparent reporting of analytical results, including measurable endotoxin levels and differences between nominal and measured quantities.

 

Research Use Limitation

• Used solely for laboratory and in vitro research
• Not approved for human consumption
• Not approved for veterinary use
• Not intended for diagnostic purposes
• Not intended for therapeutic applications
• Not permitted for clinical administration
• For research use only

• Independently analysed by Liquilabs s.r.o. Czechia
• 5-Amino-1MQ purity: greater than 99.8 % reported by COA
• Assay content measured at 51.2 mg against a nominal 50 mg
• Identification evaluated by FTIR spectrum and retention time analysis
• Molecular ion mass identified at 159 Da
• Bacterial endotoxin level of 0.350 EU/mg ± 0.007 EU/mg
• Total aerobic microbial count: 0 CFU/g
• Total yeast and mould count: 0 CFU/g
• All seven reported elemental impurities below 0.001 ppm
• Batch number: GF-5AM50-B243
• COA publication date: 11 October 2026
• Complete batch-specific COA traceability
• Synthetic small-molecule compound for NNMT and metabolic pathway research
• For research use only – not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.